Meeting
2018 Genitourinary Cancers Symposium
Selective bladder preservation with twice-daily radiation plus 5-flourouracil/cisplatin (FCT) or daily radiation plus gemcitabine (GD) for patients with muscle invasive bladder cancer: Primary results of NRG/RTOG 0712—A randomized phase 2 multicenter trial.
Authors
John J Coen
21st Century Oncology, Providence, RI
John J Coen , Peixin Zhang , Philip James Saylor , Cheryl T. Lee , Chin-Lee Wu , William Parker , Tim Lautenschlaeger , Anthony L. Zietman , Jason A. Efstathiou , Ashesh B. Jani , Omer Kucuk , Luis Souhami , Joseph P Rodgers , Howard M. Sandler , William U. Shipley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT00777491
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 408)
DOI
10.1200/JCO.2018.36.6_suppl.408
Abstract #
408
Poster Bd #
A2
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC): A multicenter, single arm phase 2 trial (SAKK 06/19).
First Author: Richard Cathomas
Poster
2024 ASCO Genitourinary Cancers Symposium
Preliminary efficacy and safety results from ReBirth: A phase II study of risk-based bladder-sparing therapy for MIBC.
First Author: Yijun Shen
Poster
2023 ASCO Genitourinary Cancers Symposium
The Bristol Bladder Trial: Five year outcomes in patients treated with neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder.
First Author: Amarnath Challapalli
Poster
2023 ASCO Genitourinary Cancers Symposium
Neoadjuvant cisplatin-based chemotherapy followed by selective bladder preservation chemoradiotherapy (CRT) in muscle-invasive urothelial carcinoma of bladder (MIBC): A combined retrospective analysis of two prospective studies.
First Author: Joohyun Hong